Liver cancer pioneer ‘Nexavar,' the star in its guidelines

By Eo, Yun-Ho | translator Alice Kang

21.09.30 14:45:29

가나다라 0

Blockbuster anticancer drug | Episode 5: Nexavar

Had maintained its sole lead for over a decade… only drug recommended as first-line

Situation has changed with the introduction of competitor drugs… sales have decreased since patent expiry

There are two reasons why new drug development is slow for a certain disease: its marketability is low or the development of the drug is difficult.

When developed, new drugs developed in the latter situation attract more widespread attention. Liver cancer (hepatocellular carcinoma) is a typical example of this. And the only targeted anticancer therapy that was available in this difficult-to-develop field of liver cancer for over 10 years was ‘Nexavar (sorafenib).’

Of course, new drugs are now available, such as ‘Stivargar (regorafenib)’ as second-line treatment, and ‘Lenvima (Lenvatinib),’ which is used as first-line treatment like Nexavar. Also, an immunotherap

Eo, Yun-Ho(unkindfish@dailypharm.com)

If you want to see the full article, please JOIN US (click)